查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1848890

肺癌手术市场依手术方式、产品类型、癌症类型和最终用户划分－2025-2032年全球预测

Lung Cancer Surgery Market by Approach, Product Type, Cancer Type, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，肺癌手术市场规模将达到 96.6 亿美元，复合年增长率为 6.10%。

关键市场统计数据
基准年 2024 60.1亿美元
预计年份：2025年 63.8亿美元
预测年份 2032 96.6亿美元
复合年增长率 (%) 6.10%

本书全面而实用地介绍了影响当代肺癌外科手术实践的临床创新、不断发展的护理模式以及商业性因素。

肺癌手术正处于曲折点，临床创新、护理模式的转变以及不断变化的报销和贸易政策正在重塑临床医生和医疗系统提供治癒性和姑息性干预的方式。影像学、手术全期护理和手术平台的进步正稳步推动复杂切除术从高风险的开放式手术转向低风险的手术方式，同时，行业整合和技术合作正在加速精密仪器在常规手术室中的应用。同时，全球供应链和关税制度的变化正在改变医院系统和门诊手术中心的筹资策略、资本规划和供应商选择流程。

本执行摘要全面分析了临床趋势、技术应用动态、供应链敏感度以及相关人员的需求，旨在清楚揭示临床实践与商业机会的交汇点。该分析基于对外科医生、医院领导、医疗器材製造商和支付方的结构化一手调查，以及对医疗器材核准、临床试验终点和监管指南的严谨二手调查。其目标是提供战术性决策，以及产品开发和上市的策略规划。

读者将从中获得一种整合的视角，将设备层面的考虑与手术流程和最终用户需求联繫起来，重点关注机器人手术和胸腔镜手术方式之间的相互作用、先进能量和缝合技术的作用，以及各种医疗环境下的操作要求。摘要优先提供清晰、可操作的观点，以帮助多学科团队将临床目标与商业性现实相结合。

不断发展的临床流程、平台整合和分散式医疗服务如何重塑肺癌手术的流程实践和商业策略

过去十年，肺癌手术领域发生了翻天覆地的变化，这主要得益于三大相互关联的因素：不断发展的临床技术、平台主导的整合以及分散式医疗服务。微创手术已从小众疗法发展成为许多可切除肿瘤的主流选择，这得益于影像技术、手术全期流程和外科医生培训计画的改进。机器人辅助胸腔镜平台和先进的胸腔镜技术使得在解剖结构受限的区域进行更精准的手术操作成为可能，缩短了患者的恢復时间，并扩大了老年合併併发症患者的手术适应症。

同时，设备生态系统正朝着平台中心化发展，视觉化、能源和装订技术的设计旨在与系统结构无缝协作。这种整合减少了流程摩擦，缩短了学习曲线，同时也强化了围绕生态系统锁定和捆绑采购模式的竞争差异化。供应商正增加对软体赋能功能的投资，例如增强视觉化、影像引导导航和流程分析，从而将价值延伸至硬体之外，并创造与耗材和服务合约相关的经常性收入来源。

门诊手术中心参与的开胸切除术相对简单，而医院则专注于病情较危急的病例。这种分散化需要适应性强的设备和精简的供应链来支持医疗服务点的多样化。同时，培训和认证计画也在扩展，以满足先进微创手术的技术要求，并强调模拟、指导和基于能力的评估。这些转变正在重新定义医疗服务提供者和製造商的临床工作流程、供应商谈判和投资重点。

了解关税变化将如何改变肺癌手术生态系统中的生产布局、采购韧性和商业性优先事项。

将于2025年生效的关税调整的累积影响将不仅限于关键采购成本，还将波及供应链、产品生命週期规划和设备筹资策略。关税调整将影响国内库存水准、区域生产布局和供应商选择等方面的决策，促使医疗系统和製造商重新评估总到岸成本和采购弹性。对于高度专业化且集中于少数全球供应商的医疗设备和耗材而言，关税带来的成本压力可能会加速大量定价、长期服务协议和本地库存安排的谈判。

製造商透过重组供应链架构来应对关税环境，例如将生产转移到低关税区、建立本地组装业务或重新设计零件以满足在地采购阈值。这些因应措施会对产品供应计画、零件物流以及资本设备交付週期的可预测性产生下游影响。对供应商而言，这意味着他们需要重新专注于采购的灵活性，包括采用多供应商筹资策略以及前置作业时间能够抵御跨境贸易波动的合约条款。

关税带来的成本压力也将影响商业性优先事项，企业可能会将市场开发重点放在贸易环境稳定的地区，而在其他地区则选择调整定价和服务模式。在临床方面，一些医院可能会推迟非紧急的资本购置，或优先考虑受跨境关税波动影响较小的模组化投资。整体而言，关税环境将改变肺癌外科手术生态系统的近期采购行为和长期策略投资选择。

从深度、细分的观点主导，将手术方法、器材类别、肿瘤组织学和医疗保健环境与采购和临床应用动态连结。

细分市场分析揭示了不同手术方式、产品类型、癌症组织学类型和治疗环境等因素对产品采纳和采购的细微影响，这些因素都会影响临床决策和商业性定位。在手术方式方面，微创手术和开放手术之间的差异尤其显着。微创手术又分为机器人辅助胸腔镜手术和视讯辅助胸腔镜手术，其中机器人系统通常被定位为高端平台，整合了先进的视觉化技术和器械。机器人辅助胸腔镜手术的典型特征是成熟的机器人平台，这些平台提供整合的人体工学和手术分析功能；而视讯辅助胸腔镜手术则分为多孔和单孔手术，这两种手术方式侧重于不同的器械配置和切口策略。这些差异会影响训练需求、手术室设置和辅助设备的需求。

产品类型进一步加剧了竞争格局的细分，其中，入路装置和套管针、内视镜和视觉化系统、能量器械以及缝合器械各自在手术效率和安全性方面发挥着不同的作用。能量器械又分为先进的双极电凝、电外科和超音波技术，每种技术在止血效果、组织损伤率和器械人体工学方面各有优劣。缝合器械分为手动缝合器和电动缝合器，电动缝合器可望在复杂角度下减轻外科医师的操作难度，并提高缝合钉的一致性。这些产品层面的差异影响采购谈判、资本预算和耗材合约。

按癌症类型进行细分也指南选择手术方案和器械需求。非小细胞肺癌包括腺癌、大细胞癌和鳞状细胞癌，每种癌症的典型肿瘤位置和切缘各不相同，这会影响手术方法和器械的选择。小细胞肺癌独特的生物学特性和治疗模式通常需要整合肿瘤治疗方案，以协调手术和全身性治疗。最后，根据最终用户（门诊手术中心和医院）进行细分，决定了医院的营运限制：门诊手术中心强调精简的器械包和快速的周转，而医院则需要处理更广泛的病例和復杂的手术全期护理。这些细分层次为整个生态系统中相关人员的市场策略、培训投资和产品蓝图提供了资讯。

美洲、欧洲、中东和非洲以及亚太地区之间的异质性将如何驱动差异化的招募、监管策略和采购选择？

区域动态正在影响肺癌外科领域的应用模式、监管重点和投资意愿。在美洲，对技术赋能疗法的重视以及高度集中的专业化医疗中心推动了对整合平台和高端耗材的需求，而医保报销体系和医院整合则影响着采购窗口和采购流程的精细化程度。临床网路和卓越中心（COE）模式促进了手术创新技术的快速推广，同时也给供应商带来了竞争压力，要求其在疗效和总医疗成本方面展现出明显的价值。

欧洲、中东和非洲各国医疗保健系统和监管趋势的差异导致了新技术应用时间的差异。西方市场倾向于透过结构化的卫生技术评估和集中采购来采纳新的外科技术，而该地区的其他部分则可能优先考虑成本效益高的解决方案和本地製造伙伴关係关係。监管协调工作和跨国临床合作通常会加速实证医学证据的产生，但不同的报销框架要求企业采取适应性强的商业性策略。

亚太地区是一个充满活力的市场，既有巨大的临床需求，又有快速发展的外科手术能力。不同市场成熟度的国家正在推行不同的策略。有些市场优先考虑快速采用机器人和胸腔外科系统，并辅以不断扩大的外科培训计画；而有些市场则专注于可扩展、低成本的解决方案，以扩大医疗服务的覆盖范围。在每个地区，供应链的韧性、关税的影响以及当地的临床证据都在影响投资决策，并决定产品特性是否符合当地的手术量和医疗机构的能力。

策略性企业策略和差异化供应商模式，结合平台拓展、证据生成和供应弹性，能带来竞争优势。

主要企业正透过平台扩张、策略联盟以及对先进视觉化、仪器连接和分析等实行技术的定向投资来巩固自身地位。现有平台供应商持续投资于模组化和服务模式，以确保耗材收入，而新兴竞争对手则专注于解决特定流程痛点或成本效益差距的利基创新。透过分销合作、共同开发契约和临床研究合作等方式开展企业间合作，仍是加速临床检验和市场准入的热门途径。

供应商策略日益重视生命週期服务，例如培训专案、监查和远端监控能力，以减少实施摩擦并展现流程的一致性。投资于证据产生（例如临床结果、比较疗效试验和真实世界数据收集）的公司在采购谈判中更具优势，因为医疗机构希望将技术支出与可衡量的品质改进联繫起来。同时，在贸易和物流不确定性的情况下，维持产品供应促使企业优化製造和供应链，包括在组装和扩大关键零件的供应商基础。

竞争动态也反映了市场进入模式的多样性。一些公司优先与大型医疗系统和综合医疗服务网路直接合作，提供打包解决方案和长期服务协议。另一些公司则透过主导管道和成本优化的设备产品，瞄准门诊手术中心和小型医院。成功的公司能够平衡临床可靠性和营运灵活性，并根据高风险医疗中心和资源受限环境的需求，调整产品蓝图。

为领导者提供切实可行的优先建议，以协调临床证据、供应链弹性、培训基础设施和适应性商业模式，从而实现永续推广。

产业领导者必须采取多管齐下的策略，将临床价值与供应链韧性和商业性灵活性结合。首先，投资可验证的临床证据和上市后研究，将设备性能与有意义的患者疗效和营运指标联繫起来。透过将技术应用与併发症、住院时间和手术时间的显着减少挂钩，相关人员可以更有力地论证基于价值的采购模式，并加速在医院和门诊环境中推广应用。其次，考虑区域组装和区域伙伴关係，以实现采购多元化，减轻关税影响，并减少前置作业时间波动。这种方法可以保障服务的连续性，并稳定大量专案的耗材供应。

第三，优先建立一套训练和能力框架，利用模拟、监考和基于能力的认证来缩短微创手术的推广应用週期。完善的培训计画不仅能提高手术安全性，还能降低机构对资本投资的抗拒。第四，设计灵活的商业模式，以适应不同的临床环境。提供模组化的资本选项、基于订阅的耗材合约和配套服务包，以满足不同终端用户的预算和营运节奏。最后，促进与临床医生和支付方的合作，共同製定将外科手术干预与更广泛的肿瘤治疗方案相结合的路径，确保设备创新能够转化为患者管理的整体改善。

一套严谨透明的研究框架，结合一手和二手研究，旨在提供可操作且有理有据的见解。

调查方法结合了系统性的原始资料收集、严谨的二手资料审查和三角验证，以确保研究结果的可靠性和有效性。原始资料收集包括对来自不同地区和医疗机构的胸腔外科医生、手术室主任、采购负责人和设备主管进行结构化访谈，并辅以现场观察，以了解工作流程的限制因素和设备利用情况。这些调查重点关注手术决策因素、培训需求、采购标准以及最终用户对设备实际性能的感知。

二次审查纳入了监管文件、临床试验註册资讯、技术指导文件和同行评审文献，以将主要研究结果置于更广泛的依证中进行解读。资料三角验证法将访谈见解与已记录的临床结果和装置註册资讯进行匹配，以识别一致的模式并调和不同的观点。透过有目的地进行细分，将研究结果按手术方法、产品类型、癌症组织学类型和最终用户类别进行映射，从而能够针对特定的临床和商业性场景提出细緻的建议。

品质保证流程包括对调查方法审核、与独立临床顾问进行检验访谈，以及根据新出现的证据不断完善结论。最终形成了一份稳健的综合报告，该报告平衡了从业人员的经验与已记录的临床和监管信号，为决策者提供了可操作且有理有据的见解。

简明扼要的结论，整合了临床创新、营运要务和商业性考量，以指南肺癌手术的策略决策。

肺癌手术的发展轨迹反映了技术成熟度、实证医学应用以及医疗服务模式转变的融合，这些因素共同为製造商、医疗服务提供者和政策制定者带来了巨大的机会和复杂的挑战。向微创手术的转变、设备生态系统的平台化以及部分手术量向门诊转移，都要求培训、采购和产品开发等各个环节进行协调应对。同时，贸易政策的变化和关税调整也要求我们密切注意供应链设计和商业性适应性。

将临床证据融入营运计画、拓展服务交付策略并投资于可扩展的培训基础设施的领导者，最能掌握临床和商业性价值。在流程能力和系统相容性日益决定技术应用的当下，策略伙伴关係、有针对性的证据生成以及灵活的商业模式将使各机构脱颖而出。透过将技术创新与医院和门诊实践的实际情况相结合，相关人员可以在保持业务绩效的同时，改善患者预后。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 越来越多地使用机器人肺叶切除系统来最大程度地减少组织损伤并加速復原。
  • 推广单孔胸腔镜手术以减少术后疼痛和住院时间
  • 术中萤光影像技术在肺切除术中精确辨识肿瘤边界
  • 应用人工智慧增强型CT分割工具对复杂肺肿瘤进行精确的术前规划
  • 将ERAS通讯协定整合到手术流程中，以改善术后效果和病患满意度。
  • 开发用于早期肺癌治疗的微创支气管镜消融方法
  • 3D列印解剖模型在指导外科手术训练和个别手术演练的应用日益广泛

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 肺癌手术市场依手术方式划分

  • 微创
    • 机器人辅助胸腔手术（大鼠）
      • 达文西系统
    • 视讯辅助胸腔镜手术（VAT）
      • 多门户
      • 统一门户
  • 开胸手术

9. 依产品类型分類的肺癌手术市场

  • 入路装置及套管针
  • 内视镜和视觉化系统
  • 能源设备
    • 先进的双极元件
    • 电外科设备
    • 超音波能量装置
  • 订书机
    • 手动订书机
    • 电动订书机

第十章 依癌症类型分類的肺癌手术市场

  • 非小细胞肺癌
    • 腺癌
    • 大细胞癌
    • 鳞状细胞癌
  • 小细胞肺癌

第十一章 肺癌手术市场（依最终用户划分）

  • 门诊手术中心
  • 医院

第十二章 各地区肺癌手术市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 肺癌手术市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国肺癌手术市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Intuitive Surgical, Inc.
    • Medtronic plc
    • Johnson & Johnson
    • Stryker Corporation
    • Olympus Corporation
    • KARL STORZ SE & Co. KG
    • Becton Dickinson and Company
    • Boston Scientific Corporation
    • Smith & Nephew plc
    • Zimmer Biomet Holdings, Inc.
Product Code: MRR-501246436957

The Lung Cancer Surgery Market is projected to grow by USD 9.66 billion at a CAGR of 6.10% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 6.01 billion
Estimated Year [2025] USD 6.38 billion
Forecast Year [2032] USD 9.66 billion
CAGR (%) 6.10%

An integrated and actionable introduction that maps clinical innovation, care model evolution, and commercial forces shaping contemporary lung cancer surgical practice

Lung cancer surgery sits at an inflection point where clinical innovation, shifting care models, and evolving reimbursement and trade policy intersect to reshape how clinicians and health systems deliver curative and palliative interventions. Advances in imaging, perioperative care, and surgical platforms have steadily moved complex resections away from high-morbidity open thoracotomy toward lower-morbidity approaches, while industry consolidation and technology partnerships have accelerated the translation of precision tooling into everyday operating rooms. At the same time, changes in global supply chains and tariff regimes are altering procurement strategy, capital planning, and vendor selection processes for hospital systems and ambulatory surgical centers.

This executive summary synthesizes clinical trends, technology adoption dynamics, supply chain sensitivities, and stakeholder imperatives to give leaders a clear line of sight into where clinical practice and commercial opportunity converge. The analysis is grounded in structured primary research with surgeons, hospital leaders, device manufacturers, and payers, supplemented by rigorous secondary review of device approvals, clinical trial endpoints, and regulatory guidance. The goal is to provide practical insight that supports tactical decisions-equipment procurement, training investments, alliance formation-and strategic planning for product development and market entry.

Readers will find an integrated view that connects device-level considerations with procedural pathways and end-user needs, highlighting the interplay between robotic and thoracoscopic modalities, the role of advanced energy and stapling technologies, and the operational requirements of different care settings. The summary prioritizes clarity and actionable intelligence so that multidisciplinary teams can align clinical goals with commercial realities.

How clinical technique evolution, platform integration, and decentralized care delivery collectively redefine procedural practice and commercial strategies in lung cancer surgery

Over the last decade, the landscape of lung cancer surgery has undergone transformative shifts driven by three interlinked vectors: clinical technique evolution, platform-driven integration, and care delivery decentralization. Minimally invasive approaches have moved from niche alternatives to mainstream options for many resectable tumors, supported by improved imaging, perioperative pathways, and surgeon training programs. Robotic assisted thoracic platforms and refined thoracoscopic techniques have enabled more precise dissection in anatomically constrained fields, reducing recovery time and widening candidacy for surgery among older and comorbid patients.

At the same time, device ecosystems have become platform-centered, whereby visualization, energy, and stapling technologies are designed to function seamlessly within a system architecture. This integration reduces procedural friction and shortens learning curves, yet it also intensifies competitive differentiation around ecosystem lock-in and bundled procurement models. Suppliers increasingly invest in software-enabled capabilities-enhanced visualization, image-guided navigation, and procedural analytics-that extend value beyond hardware and create recurring revenue pathways tied to consumables and service agreements.

Care delivery has shifted toward a more distributed model, with ambulatory surgical centers participating in less complex thoracic resections and hospitals concentrating high-acuity cases. This decentralization requires adaptable instruments and streamlined supply chains that support site-of-care diversification. Concurrently, training and credentialing programs have expanded to accommodate the technical demands of advanced minimally invasive techniques, emphasizing simulation, proctorship, and competency-based assessment. Collectively, these shifts are redefining clinical workflows, supplier negotiations, and investment priorities for providers and manufacturers alike.

Understanding how tariff changes reshape manufacturing footprints, procurement resilience, and commercial priorities across the lung cancer surgical ecosystem

The cumulative impact of tariff changes announced for implementation in 2025 extends beyond headline procurement costs and reverberates across supply chains, product lifecycle planning, and device sourcing strategies. Tariff adjustments influence decisions around domestic inventory levels, regional manufacturing footprints, and supplier selection, prompting health systems and manufacturers to reassess total landed cost and procurement resilience. For devices and consumables that are highly specialized and concentrated among a limited set of global suppliers, tariff-induced cost pressure can accelerate negotiations on bundled pricing, long-term service contracts, and local stocking agreements.

Manufacturers respond to tariff environments by reshaping supply chain architecture-either by shifting production to lower-tariff jurisdictions, establishing local assembly operations, or redesigning components to meet local content thresholds. These responses have downstream effects on product availability timelines, replacement part logistics, and the predictability of capital equipment lead times. For providers, the result is a renewed focus on procurement agility, including multi-supplier sourcing strategies and contractual terms that protect against volatility in cross-border trade.

Tariff-driven cost pressures also influence commercial prioritization, where companies may choose to concentrate market development efforts in regions with stable trade terms while adapting pricing and service models in others. Clinically, some hospitals may defer non-urgent capital acquisitions or prioritize modular investments that are less exposed to cross-border tariff fluctuations. In aggregate, the tariff landscape reshapes both near-term purchasing behavior and long-term strategic investment choices across the lung cancer surgery ecosystem.

Deep segmentation-driven perspectives that link surgical approaches, device classes, tumor histologies, and care settings to procurement and clinical adoption dynamics

Segmentation insights reveal nuanced drivers of adoption and procurement across approaches, product types, cancer histologies, and care settings, each of which influences clinical decision-making and commercial positioning. Within the approach dimension, the contrast between minimally invasive and open surgery is pronounced: minimally invasive pathways split into robotic assisted thoracic surgery and video assisted thoracoscopic surgery, with robotic systems frequently positioned as premium platforms that bundle advanced visualization and instrument articulation. Robotic assisted thoracic surgery is represented by established robotic platforms that offer integrated ergonomics and procedural analytics, while video assisted thoracoscopic surgery differentiates into multiportal and uniportal techniques that prioritize different instrument profiles and incision strategies. These distinctions affect training needs, OR setup, and accessory demand.

Product typology further refines the competitive landscape, with access devices and trocars, endoscopes and visualization systems, energy devices, and stapling devices each playing distinct roles in procedural efficiency and safety. Energy modalities divide into advanced bipolar, electrosurgical, and ultrasonic technologies, each with trade-offs in hemostasis, tissue effect, and instrument ergonomics. Stapling solutions vary between manual and powered staplers, where powered stapling can reduce surgeon effort in difficult angles and potentially improve consistency in staple formation. These product-level differences shape procurement conversations, capital budgeting, and consumable contracts.

Cancer type segmentation also guides procedural selection and device requirements. Non-small cell lung cancer encompasses adenocarcinoma, large cell carcinoma, and squamous cell carcinoma, each with differing typical tumor locations and resection margins that influence the choice of approach and instrumentation. Small cell lung cancer, with its distinct biology and treatment paradigms, often prompts integrated oncologic planning where surgery is coordinated with systemic therapy. Finally, end-user segmentation-spanning ambulatory surgical centers and hospitals-dictates operational constraints, with ambulatory centers emphasizing streamlined instrument sets and rapid turnover while hospitals manage a broader case mix and complex perioperative care. Together, these segmentation layers inform go-to-market strategies, training investments, and product roadmaps for stakeholders across the ecosystem.

How regional heterogeneity across the Americas, Europe, Middle East and Africa, and Asia-Pacific drives differentiated adoption, regulatory strategy, and procurement choices

Regional dynamics shape adoption patterns, regulatory priorities, and investment appetite across the lung cancer surgery landscape. In the Americas, a strong emphasis on technology-enabled care and a high concentration of advanced specialty centers drive demand for integrated platforms and premium consumables, while reimbursement mechanisms and hospital consolidation influence purchasing windows and procurement sophistication. Clinical networks and center-of-excellence models here facilitate rapid dissemination of procedural innovations, yet they also create competitive pressure for suppliers to demonstrate clear value in outcomes and total cost of care.

In Europe, Middle East & Africa, variability across national health systems and regulatory pathways leads to heterogeneous adoption timelines. Western European markets tend to adopt new surgical technologies through structured health technology assessment and centralized procurement, whereas other parts of this region may prioritize cost-effective solutions and local manufacturing partnerships. Regulatory harmonization efforts and cross-border clinical collaborations often accelerate evidence generation, but differing reimbursement frameworks require adaptive commercial approaches.

Asia-Pacific presents a dynamic mix of high-volume clinical demand and rapidly evolving surgical capacity. Diverse market maturity across countries drives differentiated strategies: some markets prioritize rapid uptake of robotic and thoracoscopic systems supported by expanding surgical training programs, while others emphasize scalable, lower-cost solutions to broaden access. Across all regions, supply chain resilience, tariff exposure, and local clinical evidence shape investment decisions and the prioritization of product features that align with regional procedural volumes and provider capabilities.

Strategic corporate maneuvers and differentiated supplier models that combine platform expansion, evidence generation, and supply resilience to drive competitive advantage

Leading companies are consolidating their positions through platform expansion, strategic partnerships, and targeted investments in enabling technologies such as advanced visualization, instrument articulation, and analytics. Established platform providers continue to invest in modularity and service models that lock in consumable revenue, while emerging competitors focus on niche innovations that address specific procedural pain points or cost-efficiency gaps. Cross-company collaboration-through distribution partnerships, co-development agreements, and clinical research alliances-remains a common pathway to accelerate clinical validation and market entry.

Supplier strategies increasingly emphasize lifecycle services, including training programs, proctorship, and remote monitoring capabilities that reduce adoption friction and demonstrate procedural consistency. Companies that invest in evidence generation-clinical outcomes, comparative effectiveness studies, and real-world data collection-gain an advantage in procurement conversations where institutions seek to align technology spend with measurable quality improvements. At the same time, manufacturing and supply chain optimization, including localization of assembly and broadened supplier bases for critical components, have become central to maintaining product availability amid trade and logistical uncertainty.

Competitive dynamics also reflect varied go-to-market models. Some firms prioritize direct engagement with large health systems and integrated delivery networks, offering bundled solutions and long-term service agreements, while others target ambulatory surgical centers and smaller hospitals through distributor-led channels and cost-optimized device offerings. Successful companies balance clinical credibility with operational flexibility, aligning product roadmaps to both high-acuity centers and resource-constrained settings.

Practical and prioritized recommendations for leaders to align clinical evidence, supply resilience, training infrastructure, and adaptive commercial models for sustained adoption

Industry leaders must adopt a multi-pronged approach that aligns clinical value with supply chain resilience and commercial agility. First, invest in demonstrable clinical evidence and post-market surveillance that tie device performance to meaningful patient outcomes and operational metrics. By linking technology adoption to measurable reductions in complications, length of stay, and OR time, stakeholders can strengthen value-based procurement arguments and accelerate uptake across both hospitals and ambulatory settings. Second, diversify sourcing and consider regional assembly or localized partnerships to mitigate tariff exposure and reduce lead-time variability. This approach protects service continuity and stabilizes consumable supply for high-volume programs.

Third, prioritize training and competency frameworks that shorten the adoption curve for minimally invasive techniques, leveraging simulation, proctorship, and competency-based credentialing. Robust training programs not only increase procedural safety but also reduce institutional resistance to capital investments. Fourth, design flexible commercial models that reflect site-of-care differences; offer modular capital options, subscription-based consumable agreements, and bundled service packages that align with the budgets and operational rhythms of diverse end-users. Finally, foster collaborative relationships with clinicians and payers to co-develop pathways that integrate surgical interventions with broader oncology care plans, ensuring that device innovations translate into holistic improvements in patient management.

A rigorous and transparent research framework combining primary clinician engagement, secondary evidence review, and iterative triangulation to produce actionable and defensible insights

The research methodology blends systematic primary data collection with rigorous secondary review and triangulation to ensure reliability and relevance. Primary research comprised structured interviews with thoracic surgeons, OR directors, procurement leaders, and device executives across diverse geographies and care settings, supplemented by observational site visits to understand workflow constraints and instrument utilization. These engagements focused on procedural decision drivers, training needs, procurement criteria, and real-world device performance as perceived by end-users.

Secondary review incorporated regulatory filings, clinical trial registries, technology guidance documents, and peer-reviewed literature to contextualize primary findings within the broader evidence base. Data triangulation involved cross-checking interview insights against documented clinical outcomes and device registries to identify consistent patterns and reconcile divergent perspectives. Segmentation was applied deliberately to map findings across surgical approach, product type, cancer histology, and end-user categories, enabling granular recommendations tailored to specific clinical and commercial scenarios.

Quality assurance processes included methodological audits, validation interviews with neutral clinical advisors, and iterative refinement of conclusions based on emerging evidence. The result is a robust synthesis that balances practitioner experience with documented clinical and regulatory signals, producing insights that are both actionable and defensible for decision-makers.

A concise conclusion synthesizing clinical innovation, operational imperatives, and commercial considerations to guide strategic decision-making in lung cancer surgery

The trajectory of lung cancer surgery reflects a convergence of technological maturation, evidence-driven adoption, and shifting care delivery models that together create significant opportunities and complex challenges for manufacturers, providers, and policy-makers. The move toward minimally invasive approaches, the platformization of device ecosystems, and the decentralization of certain procedural volumes to ambulatory settings demand coordinated responses across training, procurement, and product development. Simultaneously, trade policy shifts and tariff adjustments require heightened attention to supply chain design and commercial adaptability.

Leaders who integrate clinical evidence with operational planning, diversify their supply strategies, and invest in scalable training infrastructures will be best positioned to capture clinical and commercial value. Strategic partnerships, targeted evidence generation, and flexible commercial models will differentiate organizations in a landscape where procedural capability and system compatibility increasingly determine adoption. By aligning technological innovation with the practical realities of hospital and ambulatory operations, stakeholders can improve patient outcomes while sustaining business performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growing utilization of robot-assisted lobectomy systems to minimize tissue damage and accelerate recovery
  • 5.2. Expansion of single-incision thoracoscopic techniques to reduce postoperative pain and hospital stay
  • 5.3. Adoption of intraoperative fluorescence imaging for precise tumor margin identification during lung resections
  • 5.4. Implementation of AI-enhanced CT segmentation tools for accurate preoperative planning of complex lung tumors
  • 5.5. Integration of ERAS protocols in surgical workflows to improve postoperative outcomes and patient satisfaction
  • 5.6. Development of minimally invasive bronchoscopic ablation approaches for early-stage lung cancer management
  • 5.7. Rise of 3D printed anatomical models to guide surgical training and personalized procedure rehearsal

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Lung Cancer Surgery Market, by Approach

  • 8.1. Minimally Invasive
    • 8.1.1. Robotic Assisted Thoracic Surgery (Rats)
      • 8.1.1.1. Da Vinci Systems
    • 8.1.2. Video Assisted Thoracoscopic Surgery (Vats)
      • 8.1.2.1. Multiportal
      • 8.1.2.2. Uniportal
  • 8.2. Open Surgery

9. Lung Cancer Surgery Market, by Product Type

  • 9.1. Access Devices And Trocars
  • 9.2. Endoscopes And Visualization Systems
  • 9.3. Energy Devices
    • 9.3.1. Advanced Bipolar Devices
    • 9.3.2. Electrosurgical Devices
    • 9.3.3. Ultrasonic Energy Devices
  • 9.4. Stapling Devices
    • 9.4.1. Manual Staplers
    • 9.4.2. Powered Staplers

10. Lung Cancer Surgery Market, by Cancer Type

  • 10.1. Non Small Cell Lung Cancer
    • 10.1.1. Adenocarcinoma
    • 10.1.2. Large Cell Carcinoma
    • 10.1.3. Squamous Cell Carcinoma
  • 10.2. Small Cell Lung Cancer

11. Lung Cancer Surgery Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Hospitals

12. Lung Cancer Surgery Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Lung Cancer Surgery Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Lung Cancer Surgery Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Intuitive Surgical, Inc.
    • 15.3.2. Medtronic plc
    • 15.3.3. Johnson & Johnson
    • 15.3.4. Stryker Corporation
    • 15.3.5. Olympus Corporation
    • 15.3.6. KARL STORZ SE & Co. KG
    • 15.3.7. Becton Dickinson and Company
    • 15.3.8. Boston Scientific Corporation
    • 15.3.9. Smith & Nephew plc
    • 15.3.10. Zimmer Biomet Holdings, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL LUNG CANCER SURGERY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY CANCER TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. LUNG CANCER SURGERY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. LUNG CANCER SURGERY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. LUNG CANCER SURGERY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL LUNG CANCER SURGERY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL LUNG CANCER SURGERY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ROBOTIC ASSISTED THORACIC SURGERY (RATS), 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ROBOTIC ASSISTED THORACIC SURGERY (RATS), 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ROBOTIC ASSISTED THORACIC SURGERY (RATS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ROBOTIC ASSISTED THORACIC SURGERY (RATS), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ROBOTIC ASSISTED THORACIC SURGERY (RATS), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ROBOTIC ASSISTED THORACIC SURGERY (RATS), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ROBOTIC ASSISTED THORACIC SURGERY (RATS), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ROBOTIC ASSISTED THORACIC SURGERY (RATS), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY DA VINCI SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY DA VINCI SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY DA VINCI SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY DA VINCI SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY DA VINCI SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY DA VINCI SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY MULTIPORTAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY MULTIPORTAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY MULTIPORTAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY MULTIPORTAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY MULTIPORTAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY MULTIPORTAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY UNIPORTAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY UNIPORTAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY UNIPORTAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY UNIPORTAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY UNIPORTAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY UNIPORTAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY OPEN SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY OPEN SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY OPEN SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY OPEN SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY OPEN SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY OPEN SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ACCESS DEVICES AND TROCARS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ACCESS DEVICES AND TROCARS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ACCESS DEVICES AND TROCARS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ACCESS DEVICES AND TROCARS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ACCESS DEVICES AND TROCARS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ACCESS DEVICES AND TROCARS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ENDOSCOPES AND VISUALIZATION SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ENDOSCOPES AND VISUALIZATION SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ENDOSCOPES AND VISUALIZATION SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ENDOSCOPES AND VISUALIZATION SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ENDOSCOPES AND VISUALIZATION SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ENDOSCOPES AND VISUALIZATION SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ADVANCED BIPOLAR DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ADVANCED BIPOLAR DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ADVANCED BIPOLAR DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ADVANCED BIPOLAR DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ADVANCED BIPOLAR DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ADVANCED BIPOLAR DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ELECTROSURGICAL DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ELECTROSURGICAL DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ELECTROSURGICAL DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ELECTROSURGICAL DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ELECTROSURGICAL DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ELECTROSURGICAL DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ULTRASONIC ENERGY DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ULTRASONIC ENERGY DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ULTRASONIC ENERGY DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ULTRASONIC ENERGY DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ULTRASONIC ENERGY DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ULTRASONIC ENERGY DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY MANUAL STAPLERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY MANUAL STAPLERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY MANUAL STAPLERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY MANUAL STAPLERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY MANUAL STAPLERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY MANUAL STAPLERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY POWERED STAPLERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY POWERED STAPLERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY POWERED STAPLERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY POWERED STAPLERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY POWERED STAPLERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY POWERED STAPLERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ADENOCARCINOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ADENOCARCINOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ADENOCARCINOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ADENOCARCINOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ADENOCARCINOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY ADENOCARCINOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY LARGE CELL CARCINOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY LARGE CELL CARCINOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY LARGE CELL CARCINOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY LARGE CELL CARCINOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY LARGE CELL CARCINOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY LARGE CELL CARCINOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY SQUAMOUS CELL CARCINOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY SMALL CELL LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY SMALL CELL LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY SMALL CELL LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL LUNG CANCER SURGERY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY ROBOTIC ASSISTED THORACIC SURGERY (RATS), 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY ROBOTIC ASSISTED THORACIC SURGERY (RATS), 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS LUNG CANCER SURGERY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY ROBOTIC ASSISTED THORACIC SURGERY (RATS), 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY ROBOTIC ASSISTED THORACIC SURGERY (RATS), 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA LUNG CANCER SURGERY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY ROBOTIC ASSISTED THORACIC SURGERY (RATS), 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY ROBOTIC ASSISTED THORACIC SURGERY (RATS), 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA LUNG CANCER SURGERY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY ROBOTIC ASSISTED THORACIC SURGERY (RATS), 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY ROBOTIC ASSISTED THORACIC SURGERY (RATS), 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA LUNG CANCER SURGERY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY ROBOTIC ASSISTED THORACIC SURGERY (RATS), 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY ROBOTIC ASSISTED THORACIC SURGERY (RATS), 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE LUNG CANCER SURGERY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2018-2024 (USD MILLION)
  • TABLE 278. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2025-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 280. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY ROBOTIC ASSISTED THORACIC SURGERY (RATS), 2018-2024 (USD MILLION)
  • TABLE 282. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY ROBOTIC ASSISTED THORACIC SURGERY (RATS), 2025-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), 2018-2024 (USD MILLION)
  • TABLE 284. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), 2025-2032 (USD MILLION)
  • TABLE 285. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 288. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY ENERGY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, 2018-2024 (USD MILLION)
  • TABLE 290. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY STAPLING DEVICES, 2025-2032 (USD MILLION)
  • TABLE 291. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
  • TABLE 294. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY NON SMALL CELL LUNG CANCER, 2025-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 296. MIDDLE EAST LUNG CANCER SURGERY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 297. AFRICA LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 298. AFRICA LUNG CANCER SURGERY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 299. AFRICA LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2018-2024 (USD MILLION)
  • TABLE 300. AFRICA LUNG CANCER SURGERY MARKET SIZE, BY APPROACH, 2025-2032 (USD MILLION)
  • TABLE 301. AFRICA LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, 2018-2024 (USD MILLION)
  • TABLE 302. AFRICA LUNG CANCER SURGERY MARKET SIZE, BY MINIMALLY INVASIVE, 2025-2032 (USD MILLION)
  • TABLE 303. AFRICA LUNG CANCER SURGERY MARKET SIZE, BY ROBOTIC ASSISTED THORACIC SURGERY (RATS), 2018-2024 (USD MILLION)
  • TABLE 304. AFRICA LUNG CANCER SURGERY MARKET SIZE, BY ROBOTIC ASSISTED THORACIC SURGERY (RATS), 2025-2032 (USD MILLION)
  • TABLE 305. AFRICA LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), 2018-2024 (USD MILLION)
  • TABLE 306. AFRICA LUNG CANCER SURGERY MARKET SIZE, BY VIDEO ASSISTED THORACOSCOPIC SURGERY (VATS), 2025-2032 (USD